We investigated the relationship between mefloquine antimalarial treatment and the outcome of pregnancy in Karen women living in an area along the western border of Thailand where multidrugresistant Plasmodium falciparum infections are common. Of 3,587 pregnancies investigated, 208 (5.8%) were exposed to mefloquine, 656 (18.3%) to quinine only, and 909 (25.3%) to other antimalarials, and 2,470 (68.9%) had no documented malaria. There were 61 stillbirths and 313 abortions. Women who received mefloquine treatment during but not before pregnancy had a significantly greater risk of stillbirth than did women treated with quinine alone (odds ratio [OR], 4.72; 95% confidence interval [CI], 1.7 -12.7), women exposed to other treatments (OR, 5.10; 95% CI, 2 -13.1), and women who had no malaria (OR, 3.50; 95% CI, 1.6 -7.6) (P õ .01). This association remained after adjustment for all identified confounding factors. Mefloquine was not associated with abortion, low birth weight, neurological retardation, or congenital malformations. Mefloquine treatment during pregnancy was associated with an increased risk of stillbirth.
The use of the antimalarial mefloquine has increased in recent
As part of the detailed postmarketing monitoring by the manufacturer in collaboration with the World Health Organization years because of the spread of Plasmodium falciparum strains that are resistant to other available drugs. Mefloquine is pre-(Geneva), a total of 1,500 pregnancies exposed to mefloquine immediately before or during the first 3 months of pregnancy scribed widely as prophylaxis for malaria in travelers and for the treatment of uncomplicated P. falciparum infections in areas have been documented prospectively [6] . More than 95% of the women took mefloquine for prophylaxis, and the outcomes for of endemicity where the level of resistance is high, such as in Southeast Asia and South America [1] . The toxicity of meflo-971 (64%) could be evaluated. There were 8 stillbirths (0.8%) and 79 spontaneous abortions (1 chromosomal disorder and 4 quine has been studied extensively [2] and the drug is relatively well tolerated. Potentially serious neuropsychiatric reactions [3] placental disorders); 246 women had abortions induced because of concerns over the potential risks (5 malformations were oboccur in Ç1/10,000 healthy subjects receiving mefloquine prophylaxis, 1/1,000 Asian patients, 1/200 Caucasian or black Afriserved). Of the remaining 646 women who delivered, 26 (4%) (95% CI, 2.5-5.6) had a baby with one or more congenital can patients with uncomplicated malaria, and 1/20 patients recovering from severe malaria following mefloquine treatmalformations, 33 had other pregnancy-related problems, and 587 had normal babies. Thus, the prevalence of congenital malment [4] .
The manufacturer of mefloquine (Lariam; Hoffman La Roche, formations or adverse outcomes in this cohort was not significantly different from the prevalence observed in the general Basel, Switzerland) recommends avoidance of mefloquine during pregnancy because of lack of data on its safety for the fetus population (1.5%-2.0%) [7] . However, an accurate risk ratio cannot be calculated from these retrospective data because the [5] . In animal studies, mefloquine causes fetal toxicity at doses 5-20 times higher than those recommended for human use [2] . number of exposed pregnant women is unknown. Studies on the use of mefloquine in prophylaxis during the second half of pregnancy have concluded that the drug is safe [8, 9] , but there are few data on the effects of fetal exposure to mefloquine given for the treatment of malaria during early gestation, and the drug 809 CID 1999; 28 (April) Mefloquine Treatment in Pregnancy records of all women seen in the ANCs to identify those who microscopically confirmed uncomplicated P. falciparum infections. were exposed to mefloquine in pregnancy. All women who could be found were interviewed. We have compared the outSince 1986, pregnant women living in the camps have been invited to attend a weekly consultation aimed at the early deteccomes of these pregnancies to those of women exposed to other antimalarial drugs or who did not have malaria in pregnancy.
tion and treatment of malarial infections. The antenatal consultations were conducted by the staff of the Shoklo Malaria Research Unit (SMRU) in the northern camps of Bonoklo, Shoklo,
Patients and Methods
and Mae Salit (total population, 15,000), 20 -50 km north of the Thai border town of Mae Than, and by the staff of MSF
Study Design
in the southern camps of Kamolekaw, Maela, Wangka, and The investigation was a retrospective comparison of the outMawker. In this community falciparum malaria is associated comes of pregnancies in women exposed to mefloquine to those with significant maternal mortality and morbidity [10] . Alof women not exposed to mefloquine, either because they were though mortality was reduced considerably by early weekly treated with other antimalarials or they had no documented screening, parasitemic episodes due to P. falciparum were still episodes of malaria during pregnancy. The study was designed associated with maternal anemia and a reduction in the mean initially to investigate the potential effects on outcome of birth weight. These deleterious effects were most marked in mefloquine treatment exposure just before and in early pregthe primigravida but were also evident in the second and third nancy (i.e., 03 to /4 months' gestation). Exposure up to 3 pregnancies. months before conception was included prospectively because During the first 12 weeks of pregnancy, uncomplicated of the long terminal elimination half-life of mefloquine in adult P. falciparum infections were treated with quinine sulfate (from females (Ç3 weeks) [11] . The investigation was later extended the Government Pharmaceutical Organization of Thailand) at to the entire pregnancy. a dosage of 10 mg salt/kg three times a day for 7 days. P. falciparum episodes during the second and third trimesters were treated with either quinine (as above) or single-dose Population mefloquine (25 mg base/kg; Lariam). The two organizations The study population consisted of Karen women living in providing antenatal care had different treatment policies; the refugee camps along the malarious northwestern border of SMRU used mefloquine more readily because of the decline Thailand. Health care was provided by Médecins sans Fronin quinine efficacy and the poor compliance with 7-day quinine tières (MSF) and food was distributed by a consortium of chariregimens, whereas MSF tended to use quinine as first-line treatties. In a census conducted in 1992, it was estimated that 8,960 ment and to reserve mefloquine for treatment failures. All cliniwomen were older than 15 years, in a total population of cal and laboratory information from the ANCs was recorded 32,000. The annual birth rate was estimated to be 40 per 1,000.
on individual records and entered into a computerized database. The number of children õ1 year of age was Ç1,400. The This data set, containing 5,012 records (pregnancies), was used mortality rate among infants (aged õ1 y) was estimated to be to trace women who might have been exposed to mefloquine 160/1,000. during pregnancy after 1987.
Epidemiology and Treatment of Malaria Interviews, Data Collection
Five Karen interviewers were trained specifically for the study The main medical problem confronting the population is multidrug-resistant falciparum malaria [12] . The epidemiology and were responsible for tracing the women and conducting the interviews. The 2,411 women (from the 5,012 records of the of malaria in this community has been described recently [13] . In brief, this is an area of low and seasonal transmission of ANC database) who could be traced were interviewed in their own language. Exposure was confirmed by cross-checking the P. falciparum and Plasmodium vivax, and the two groups at greatest risk of severe infections are children õ5 years of age women's answers to specific questions with their records in the ANC database and the clinic records of malaria treatment. The and pregnant women. The incidence of falciparum malaria in this population was estimated to be 400 per 1,000 per year in interviewing teams used a demonstration set of unlabelled tablets to help the women identify which antimalarial drugs they might 1994. Between 1985 and 1990 uncomplicated falciparum malaria in nonpregnant patients was treated with the combination have been given before or during pregnancy. The outcome variables investigated were stillbirth, abortion, mefloquine/sulfadoxine/pyrimethamine (Fansimef, Hoffman La Roche) [14] . In 1991 this was changed to high-dose (25 and malformation rates; birth weight; and the baby's neurological development, assessed from the age that the baby sat, mg/kg) mefloquine alone because of increased resistance of P. falciparum [15] . All treatments with mefloquine were superwalked, and talked. Malformations of children alive at the time of the interview were examined by a nurse from the team and vised. The clinics were the only source of prescriptions of the drug in the camps. Mefloquine was prescribed only for confirmed by a physician from the SMRU. received mefloquine as prophylaxis were excluded from the analysis. The distributions of the studied population and the It was possible to review and verify 2,440 questionnaires overall population registered in the ANC file were compared (68%) from the study sample pregnancies and compare them for age and gravidity (by Student's t test) and for medical site, to the ANC records. For 2,138 (87.6%) of the study questionexposure to malaria and antimalarial drugs, and abortion and naires, there were no differences in malaria episodes docustillbirth rates (by x 2 tests). All the distributions of the demomented in the ANC cards and reported by the mothers in the graphic variables were presented and statistical tests were perstudy. For 1,744 (71.5%) of the cases, there was no difference formed to identify any confounding variables for exposure. in exposure to malaria and treatments recorded. The mean time Univariate analyses were performed to see if use of mefloquine between delivery and interview was significantly higher for (compared with use of quinine, other antimalarial drugs, and no women who forgot to declare a malaria episode when interantimalarials) during pregnancy was a risk factor for stillbirth, viewed. For the validity of declaration of stillbirth, there was abortion, perinatal death, neurological retardation, unexplained no significant difference in the percentages of potential errors abnormalities, and low birth weight. Multiple logistic regresof classification between the two main categories of exposure, sion was used to adjust for any confounding variables identii.e., mefloquine vs. no mefloquine. Altogether, there was corfied. rect classification of outcome for 88% of the comparable obserSubanalyses were also performed to calculate the relative vations. Thus, the misclassification observed can be defined as risk of adverse outcome associated with mefloquine during the nondifferential. All confirmed errors were corrected with the periods of from 03 months to conception, from conception to assumption that the ANC card (completed during pregnancy) 4 months' gestation, and from ú4 months' gestation to birth. was the true reflection of reality.
The level of significance for all analyses was 5%. The analyses were computed with use of the statistical packages Epi Info
Definitions
(version 6, CDC public domain software) and SPSS for Windows (SPSS Benelux, Gorinchem, the Netherlands). The origiThe exposure groups chosen prospectively for analysis were nal goal was to have a sample size of 2,790 pregnancies, of pregnancies exposed during or in the 3 months before concepwhom 186 had been exposed to mefloquine, in order to detect tion to (1) From 5,012 records in the ANC database, a total of 3,587 pregnancies were investigated between July 1991 and June 1994. The gestational age at the time of drug exposure was calculated from the date of the last menstruation or, preferably, the For the 1,425 remaining pregnancies, the women could not be traced. Table 1 summarizes the demographic characteristics of fundal height in the last days before delivery and the newborn's Dubowitz score (when available). Stillbirth was defined as the this cohort. The study cohort was generally comparable to the overall ANC population. The proportion of women who had at delivery after ú28 weeks' gestation of a fetus that did not breathe. Abortion was defined as the expulsion of a fetus before least one episode of falciparum malaria was similar in both populations: 28.3% (27.0%-29.6%) and 28.1% (26.6%-the 28th week of gestation. The cut-off gestational age for abortion is higher than in developed countries because in this 29.5%), respectively. However, the rate of past abortion was lower in the study cohort than in the overall ANC population. setting, in the absence of resuscitation facilities and intensive care, a fetus 28 weeks old or younger is not viable. Because Furthermore, the proportion of pregnant women living in southern camps who were recruited for the study was higher than the most of the deliveries in this community occur at home and without supervision, the diagnosis of stillbirth was mainly selfproportion in the overall pregnant-women population (P õ .001). There were 208 pregnancies (5.8%) exposed to mefloquine reported. The birth weight was measured within 24 hours with a Salter scale (Salter, Birmingham, United Kingdom), and low (group A), 656 (18.3%) exposed to quinine only (group B), and 909 (25.3%) exposed to antimalarial drugs other than birth weight was defined as a body weight of õ2,500 g. For assessment of neurological development, the mean ages for mefloquine (group C). In 2,470 pregnancies (68.9%), there was no documented malaria or antimalarial treatment (group D). sitting, walking, and talking were calculated, and retardation was defined as a value more than 2 standard deviations above Women who grew up in an area where malaria is endemic had a lower risk of having malaria during their pregnancy (RR, the mean for the population.
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03-19-99 05:11:02 cida UC: CID exposed to mefloquine either during pregnancy or in the 3 months before conception (group A) were at greater risk of having a stillbirth than were women in groups B (OR Å 4.0; 95% CI, 1.4 -11.6), C (OR Å 4.5; 95% CI, 1.6 -12.9), and D 0.80; 95% CI, 0.74 -0.85). The pregnant women exposed to (OR Å 3.1; 95% CI, 1.2 -7.6) (table 2). mefloquine were slightly but significantly younger than the These odds ratios were adjusted for the following confoundwomen exposed to other treatments. Their ages (mean { SD) ing variables: mother's age, gravidity, camp location, and numwere 25 { 6 and 26 { 6 years, respectively (P Å .035). Both ber of documented malaria attacks. The 61 stillbirths were later groups were significantly younger than the women who did divided into two categories: those that could be explained on not experience malaria during their pregnancy (27 { 6 years; the basis of the information available (38 patient records), and P õ .001).
those for which no information was available (23 records not There was a higher proportion of primigravidae in the mefloquine-exposed group (32%) than in the group of women exposed to other antimalarials (29.7%) or in the nonexposed group (20.5%) (P õ .001). The proportion who had malaria verifiable). Table 3 summarizes the main causes of stillbirth.
Risk Factors for Abortions
There were no significant differences between the groups of The percentages of abortions were 3.9% in group A, 3.5% mefloquine-exposed and -unexposed pregnancies in terms of in B, 4.0% in C, and 10.9% in D (P õ .001). Women who the proportion of explained stillbirths (x 2 Å 0.4; P Å .8).
did not have malaria during pregnancy had a significantly However, it should be noted that for all the stillbirths occurring higher risk for abortion than women exposed to mefloquine in the mefloquine-treated group there was a possible explana-(RR Å 2.8; 95% CI, 1.4 -5.6; P Å .001) or quinine (RR Å tion (table 3). 3.1; 95% CI, 2.1 -4.7; P õ .001). As the primary objective was to identify potential effects of mefloquine exposure in the early stage of gestation, the analysis
Risk Factors for Low Birth Weight
was performed for each of the predefined time periods of exposure: (1) from 3 months before conception to conception, (2) Birth weight was not documented in 543 live births. Having from conception to 4 months' gestation, and (3) from ú4 at least one episode of malaria during pregnancy was a sigmonths' gestation to birth. The time delay between the treatment and the event (stillbirth) could not be included in the was not found to be a significant risk factor for stillbirth. respectively (table 5) . retardation: babies delivered in southern camps were at higher risk of retardation (OR Å 2.7; 95% CI, 1.9 -4.0; P õ .001).
Stage, malaria treatment Stillbirths (IR)* OR (95% CI)
However, the median (range) time delay from delivery to the first interview in the group from the northern camp was 5 Of the 66 malformations (1.7%) reported (table 6) , only 39
From 4 mo to end of pregnancy could be investigated. There were no differences in the risk of associated with an increased risk of stillbirth. This remained nificant risk factor for low birth weight (OR Å 1.5; 95% CI, (no malaria).
Unknown 5
The risk for low birth weight decreased with the mother's The number of stillbirths in the mefloquine group was only nine, and odds ratios presented here are small and the confivariables: mother's age, camp location, gravidity, and malaria attack rates. The risk was significant for the two predefined dence intervals wide. This is a relatively large series documenting mefloquine treatment in pregnant women. Overall, 131 periods, which together comprised the entire pregnancy: from conception to 4 months and from ú4 months to delivery. In women were exposed to the drug after the start of the gestation. The outcomes of these mefloquine-exposed pregnancies were the first period, mefloquine exposure (group A) carried a significantly higher risk than the two other treatment exposure compared to those of women from the same community and the same ethnic group who were exposed either to other antimagroups (B and C) but not the group with no malaria exposure, although the number of stillbirths was small (2 in group A, 1 larials or to neither malaria nor antimalarial drugs. Potential confounders were controlled for. The increased risk of stillbirth in group B, 2 in group C, and 19 in group D) and the confidence intervals were very wide (1.04 -579 and 1.48 -126 for groups associated with mefloquine remained even when the women who received the fixed combination of mefloquine/sulphadox-B and C, respectively) (table 5).
For the second period, the risk of stillbirth following mefloine/pyrimethamine (Fansimef) were removed from the analysis (data not shown). quine exposure was again higher than in the other groups, but this difference did not reach significance when compared with There are only five previous reports on the use of mefloquine in pregnancies of which the outcomes are documented. Harinathe quinine-alone group (B). In identifying associations with stillbirth, it is obviously difficult to exclude all possible consuta et al. [16] treated 85 women with mefloquine and compared the outcomes to those for 72 women treated with quinine. founding factors, and it is difficult to envisage a mechanism that could explain this relatively rare effect, resulting from
No differences in stillbirth rates were found. Steketee et al. [9] reported the outcome of 932 pregnancies of women exposed exposure to mefloquine anywhere between the first and the last month of gestation.
to mefloquine as weekly prophylaxis. Second-trimester death and perinatal mortality were stated as unrelated to the drug [9] . The stability and isolation of the camps made it possible to document almost all malaria episodes in a community that had Phillips-Howard et al. reported the findings on a cohort of 331 women exposed to mefloquine during pregnancy [17] . In their no other source of mefloquine. The study population constitutes a representative sample of the entire cohort of pregnant women study the rate of spontaneous abortions was significantly higher with use of mefloquine (9.1%) than with use of Fansidar (2.6%) followed in the ANCs during the same period, which makes a possible selection bias improbable. The differences in rates of (P Å .01), but these were similar to the background rates in the unexposed population (between 7% and 11%). These auabortions (both past and present) probably reflect more active data collection in the study than in the general population. Each thors also reported a higher rate of induced abortions among the mefloquine-exposed women. These findings are similar to woman recruited in the study was asked specifically about past miscarriages and about the outcome of the pregnancy investithose of Smoak et al. in a cohort of U.S. female soldiers [18] . Previously we conducted a double-blind, placebo-congated. By contrast, abortions in women outside the study were seldom reported, especially those occurring in the first trimestrolled trial of mefloquine antimalarial prophylaxis in the second half of pregnancy [8] , in the same community as in this ter. However, the closer to term, the more likely it was that a fetal death would be noted by the midwives in charge of the investigation. We observed an excess in the rate of stillbirths in the mefloquine group (RR Å 2.63; 95% CI, 0.86 -8.08) but ANC, and, in support of this, the rates of stillbirth in the study and the ANC were similar.
concluded that, as the stillbirths resulted from a variety of identified causes and as the confidence interval was wide, this The apparent increased risk of abortion in the women who did not have malaria was expected because women who have was probably a chance finding and not a result of maternal exposure to mefloquine. However, taken together with the an abortion (more often in the first trimester) are less likely to be infected during such short gestation. The majority of the current findings, this provides further support for a causal link in this community. study questionnaires could be verified against the medical records of the ANC. For the classification of mefloquine exposure
The finding that there was also an increased risk of stillbirth in pregnant women treated with mefloquine in the 3 years and of the main endpoint (stillbirth), 90% of the records were found to be correct.
following the study presented here also provides support for a causal relationship between mefloquine and stillbirth, but it There are several reasons to be cautious in interpreting these results. The study was conducted over a 3-year period in diffishould be stressed that this result comes from an analysis of the ANC clinical records and not from interviews. The risk cult circumstances. The camps are scattered over a 120-km distance and relatively inaccessible. It was not possible for was statistically significant only in one of the comparisons (i.e., mefloquine vs. quinine and others) and again with a wide physicians to supervise all interviews, and it was even more difficult for them to assist in the deliveries. As a result, full confidence interval (OR Å 3.36; 95% CI, 1.04 -10.85; P Å .04). clinical details on stillbirths were unavailable in most cases. The information was collected from the mothers' interviews;
The rates of fetal wastage and congenital abnormalities in this study do not differ from the rates in other areas with therefore, a memory bias could exist.
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